Mestag Therapeutics
Founded 2020 Β· 5 known investors
Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets. It advances its own pipeline while partnering with pharmaceutical companies such as MSD and Johnson & Johnson.
AI & Machine LearningBiotechHealthtech
Founders & leadership
SH
Susan HillFounder & Chief Executive Officer
MB
Michael B. BrennerFounder
CB
Chris BuckleyFounder
MC
Mark ColesFounder
SR
Soumya RaychaudhuriFounder
DA
David A. TuvesonFounder
LR
Lindsey RolfeChief Medical Officer
PM
Pascal MerchiersChief Development Officer
RD
Robert de JongeChief Business Officer
GE
Greg ElsonHead of CMC
Investors Β· 5
Frequently asked questions
- What does Mestag Therapeutics do?
- Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets. It advances its own pipeline while partnering with pharmaceutical companies such as MSD and Johnson & Johnson.
- Who founded Mestag Therapeutics?
- Mestag Therapeutics was founded by Susan Hill, Michael B. Brenner, Chris Buckley, Mark Coles, Soumya Raychaudhuri, David A. Tuveson in 2020.
- Who are Mestag Therapeutics's investors?
- Mestag Therapeutics's investors include GV (Google Ventures), Forbion, Johnson & Johnson Innovation β JJDC, Northpond Ventures, SV Health Investors.